Research Article: Anti-Glioma Effects of Ligustilide or n-Butylphthalide on Their Own and the Synergistic Effects with Temozolomide via PIK/Akt Signaling Pathway
Abstract:
Graphical Abstract:
Introduction:
Glioblastoma (GBM) is the most common and aggressive primary brain tumor, with a median survival of less than one year. In the past years, the incidence of glioma has been increasing at a rate of –% per year. Current approaches to therapy include surgery, radiotherapy, and chemotherapy, as well as emerging gene therapy and immunotherapy in recent years; however, the results are unsatisfactory. Temozolomide (TMZ) is an oral alkylating agent and has been widely applied as an effective first-line chemotherapeutic…
Read more